Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA expands Mounjaro approval to reduce cardiovascular risk

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at beckershospitalreview.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

The FDA has approved Mounjaro (tirzepatide) to reduce major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, based on data showing an 8% lower event rate compared to Trulicity.

This Wire brief sits within Fusion42's coverage of Medtech, and 20 sources have reported it between 28 Aug 2026 and 1 Sep 2026.

◆ ◆ The Wire takeaway

You face new barriers and opportunities as the FDA broadens heart-protection claims for diabetes drugs. Expect payers and providers to demand evidence of cardiovascular benefits alongside glucose control.

◆ Coverage

20 sources · first reported 28 Aug 2026 · latest 1 Sep 2026

◆ Topics

MedtechFDA-approvalcardiovascular-risktype-2-diabetesmedtechdrug-approval